2026-04-17T17:07:13Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1737592025-12-05T12:07:26Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT
author
Roger, Albert
author
Malet, Alfons
author
Moreno, Victoria
author
Parra, Antonio
author
Gutierrez, Diego
author
Lleonart Bellfill, Ramon
author
Moreno, Francisco
author
Valero, Antonio
author
Navarro, Begoña
author
Hinojosa, Belén
author
Justicia, José L.
2021-02-09T09:36:19Z2021-02-09T09:36:19Z2020-01-012021-02-08T10:12:28Z
Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus((R)) in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting.
cc by-nc-nd (c) Roger et al., 2020 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess
Àcars
Rinitis
Mites
Rhinitis
Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion